Terms: = Prostate cancer AND IL6ST, CDw130, 3572, ENSG00000134352, P40189, IL6R-beta, GP130-RAPS, GP130, CD130 AND Treatment
13 results:
1. SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis.
Liu S; Li X; Lin Z; Su L; Yan S; Zhao B; Miao J
Cancer Lett; 2018 Mar; 416():11-23. PubMed ID: 29247827
[TBL] [Abstract] [Full Text] [Related]
2. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in cancer: Challenges and Opportunities.
Kampan NC; Xiang SD; McNally OM; Stephens AN; Quinn MA; Plebanski M
Curr Med Chem; 2018; 25(36):4785-4806. PubMed ID: 28707587
[TBL] [Abstract] [Full Text] [Related]
3. SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in prostate cancer Cells.
Handle F; Erb HH; Luef B; Hoefer J; Dietrich D; Parson W; Kristiansen G; Santer FR; Culig Z
Mol Cancer Res; 2016 Jun; 14(6):574-85. PubMed ID: 27053681
[TBL] [Abstract] [Full Text] [Related]
4. Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma.
Hafeez BB; Zhong W; Weichert J; Dreckschmidt NE; Jamal MS; Verma AK
Cancer Res; 2011 Mar; 71(6):2318-27. PubMed ID: 21406403
[TBL] [Abstract] [Full Text] [Related]
5. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Zhao W; Jaganathan S; Turkson J
J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
[TBL] [Abstract] [Full Text] [Related]
6. Interleukin-6 regulates androgen synthesis in prostate cancer cells.
Chun JY; Nadiminty N; Dutt S; Lou W; Yang JC; Kung HJ; Evans CP; Gao AC
Clin Cancer Res; 2009 Aug; 15(15):4815-22. PubMed ID: 19638459
[TBL] [Abstract] [Full Text] [Related]
7. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention.
Crispen PL; Uzzo RG; Golovine K; Makhov P; Pollack A; Horwitz EM; Greenberg RE; Kolenko VM
Prostate; 2007 May; 67(6):582-90. PubMed ID: 17262802
[TBL] [Abstract] [Full Text] [Related]
8. Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
Godoy-Tundidor S; Cavarretta IT; Fuchs D; Fiechtl M; Steiner H; Friedbichler K; Bartsch G; Hobisch A; Culig Z
Prostate; 2005 Jul; 64(2):209-16. PubMed ID: 15712220
[TBL] [Abstract] [Full Text] [Related]
9. Constitutive activation of gp130 leads to neuroendocrine differentiation in vitro and in vivo.
Palmer J; Ernst M; Hammacher A; Hertzog PJ
Prostate; 2005 Feb; 62(3):282-9. PubMed ID: 15389784
[TBL] [Abstract] [Full Text] [Related]
10. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.
Xie S; Lin HK; Ni J; Yang L; Wang L; di Sant'Agnese PA; Chang C
Prostate; 2004 Jun; 60(1):61-7. PubMed ID: 15129430
[TBL] [Abstract] [Full Text] [Related]
11. Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/gp130/STAT-3 signaling pathway.
Liu XH; Kirschenbaum A; Lu M; Yao S; Klausner A; Preston C; Holland JF; Levine AC
Biochem Biophys Res Commun; 2002 Jan; 290(1):249-55. PubMed ID: 11779161
[TBL] [Abstract] [Full Text] [Related]
12. Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity.
Borsellino N; Bonavida B; Ciliberto G; Toniatti C; Travali S; D'Alessandro N
Cancer; 1999 Jan; 85(1):134-44. PubMed ID: 9921985
[TBL] [Abstract] [Full Text] [Related]
13. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells.
Qiu Y; Ravi L; Kung HJ
Nature; 1998 May; 393(6680):83-5. PubMed ID: 9590694
[TBL] [Abstract] [Full Text] [Related]
